98%
921
2 minutes
20
Children with global developmental delay (GDD) were trained with the Portage Guide to Early Education (PGEE) program.In the treatment group, the PGEE program was performed on children with GDD (45 cases) through a combination of family and hospital interventions, in a 1-to-1 ratio. The Gesell Infant Development Scale (GESELL) developmental quotient (DQ) and social adaptability were measured before and 6 months after PGEE implementation in the treatment group. These parameters were also evaluated in a control group (30 cases) during an initial visit and 6 months later.Before the PGEE intervention, no significant differences were observed between the general characteristics of children in the control and treatment groups. Six months after the PGEE intervention, the DQ values of the children with GDD in the treatment group (64.7 ± 9.5) were significantly higher than those before treatment (54.6 ± 9.3) and those of the control group (58.3 ± 10.2) (P < .05). The PGEE intervention significantly increased the DQ values on 5 aspects, including gross motor, fine motor, adaptability, language, and personal social activity abilities, and the scores on the Infants-Junior Middle School Students' Social-Life Abilities Scales (SM scales), as compared with the control group (P < .05).The PGEE program improves the DQ, social adaptability, and prognosis of children with GDD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203492 | PMC |
http://dx.doi.org/10.1097/MD.0000000000012202 | DOI Listing |
JMIR Res Protoc
September 2025
Institute of Higher Education and Research in Healthcare, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Background: In pediatric intensive care units, pain, sedation, delirium, and iatrogenic withdrawal syndrome (IWS) must be managed as interrelated conditions. Although clinical practice guidelines (CPGs) exist, new evidence needs to be incorporated, gaps in recommendations addressed, and recommendations adapted to the European context.
Objective: This protocol describes the development of the first patient- and family-informed European guideline for managing pain, sedation, delirium, and IWS by the European Society of Paediatric and Neonatal Intensive Care.
Integr Environ Assess Manag
September 2025
Water Research Group, Unit for Environmental Sciences and Management, North-West University, Potchefstroom, South Africa.
Pesticides are widely used to meet the food demands of a growing population, with various types used to control pests depending on the crops grown. Rainfall, overspray, and runoff from agricultural fields can wash these insecticides into water bodies, posing documented environmental risks. Imidacloprid is commonly used in Afrotropical regions such as South Africa, yet limited information is available on its toxicity to aquatic ecosystems within this climate region.
View Article and Find Full Text PDFBackground: People with opioid use disorder (OUD) often exhibit high rates of nonprescribed drug use and low retention on buprenorphine. This study tested the feasibility, acceptability, and preliminary efficacy of an intervention combining peer recovery coaching and CBT4CBT-buprenorphine (CBT4CBT+RC) to reduce nonprescribed drug use and increase buprenorphine retention.
Methods: A randomized trial conducted from December 15, 2020, to November 24, 2021, compared an 8-week CBT4CBT+RC intervention to treatment as usual (TAU).
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
Clin Transl Sci
September 2025
Food and Drug Administration, Silver Spring, Maryland, USA.
Since the first decentralized clinical trial (DCT) was conducted in 2011, there has been an increased usage of DCT due to its benefits of patient-centricity and generalizability of findings. This trend was further expedited by the global COVID-19 pandemic. We identified 23 case studies across various therapeutic areas and grouped them into different categories according to their purposes-by necessity, for operational benefits, to address unique research questions, to validate innovative digital endpoints, or to validate decentralization as a clinical research platform.
View Article and Find Full Text PDF